What's in AZ Jan Palfijn Gent's pipeline?

AZ Jan Palfijn Gent has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with AZ Jan Palfijn Gent's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/az-jan-palfijn-gent.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

AZ Jan Palfijn Gent — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZ Jan Palfijn Gent pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
hp-FSH	hp-FSH	marketed
Decapeptyl Daily	Decapeptyl Daily	marketed
low dose hCG	low dose hCG	marketed
GnRh agonist +1500E hCG	GnRh agonist +1500E hCG	marketed	GnRH agonist with hCG supplementation	GnRH receptor; LH receptor (via hCG)	Reproductive/Fertility
pregnyl	pregnyl	marketed			Other

Therapeutic area mix

Other · 1
Reproductive/Fertility · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for AZ Jan Palfijn Gent:

Cite this brief

Drug Landscape (2026). AZ Jan Palfijn Gent — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/az-jan-palfijn-gent. Accessed 2026-05-16.